Literature DB >> 27460740

microRNA-181a is upregulated in human atherosclerosis plaques and involves in the oxidative stress-induced endothelial cell dysfunction through direct targeting Bcl-2.

G Liu1, Y Li, X-G Gao.   

Abstract

OBJECTIVE: Atherosclerosis is featured as artery wall thickness as a result of invasion and accumulation of white blood cells and proliferation of intimal smooth muscle cells. Endothelial dysfunction has been linked to a variety of vascular diseases, including atherosclerosis. MicroRNAs play essential roles during the atherosclerotic plaques formation. In this study, we investigate the roles of miR-181a in the oxidative stress-induced endothelial cells dysfunction.
MATERIALS AND METHODS: The expressions of miR-181a were compared between human atherosclerotic plaques and normal blood vessels. The Bcl-2 protein expression was measured by Western blot and mRNA expression was measured by qRT-PCR. HUVECs were transiently transfected with pre-miR-181a or control microRNAs by Lipofectamine 2000. The viability of HUVECs in response to H2O2 was measured by MTT assay.
RESULTS: We report miR-181a is upregulated in human atherosclerotic plaques compared with the normal blood vessel. The miR-181a is induced by H2O2 treatments. The exogenous overexpression of miR-181a accelerates the apoptosis rates of HUVECs in response to H2O2. We identify Bcl-2 as a direct target of miR-181a. Also, we observed H2O2 treatments inhibited Bcl-2 expressions at both protein and mRNA levels. Inhibition of miR-181a restores Bcl-2 expressions, leading to increased resistance to H2O2. Moreover, restoration of Bcl-2 in miR-181a-overexpressing HUVECs renders cells tolerate higher concentrations of H2O2. Finally, a reverse correlation between miR-181a and Bcl-2 expression in human atherosclerosis plaques is illustrated.
CONCLUSIONS: Our results revealed an essential role of miR-181a in the development of atherosclerosis through the regulation of the endothelial dysfunction, providing mechanisms for the development of new antioxidant drugs for the treatment of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27460740

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Long noncoding RNA MEG3 suppressed endothelial cell proliferation and migration through regulating miR-21.

Authors:  Ziheng Wu; Yangyan He; Donglin Li; Xin Fang; Tao Shang; Hongkun Zhang; Xiangtao Zheng
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

2.  Downregulation of miR-34a promotes endothelial cell growth and suppresses apoptosis in atherosclerosis by regulating Bcl-2.

Authors:  Gang Su; Guangli Sun; Hai Liu; Liliang Shu; Zhenxing Liang
Journal:  Heart Vessels       Date:  2018-04-27       Impact factor: 2.037

Review 3.  MicroRNAs and obesity-induced endothelial dysfunction: key paradigms in molecular therapy.

Authors:  Karima Ait-Aissa; Quynh My Nguyen; Mohanad Gabani; Adam Kassan; Santosh Kumar; Soo-Kyoung Choi; Alexis A Gonzalez; Tahsin Khataei; Amal M Sahyoun; Cheng Chen; Modar Kassan
Journal:  Cardiovasc Diabetol       Date:  2020-09-09       Impact factor: 9.951

Review 4.  Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target?

Authors:  Thomas Senoner; Wolfgang Dichtl
Journal:  Nutrients       Date:  2019-09-04       Impact factor: 5.717

5.  miR‑15a represses cancer cell migration and invasion under conditions of hypoxia by targeting and downregulating Bcl‑2 expression in human osteosarcoma cells.

Authors:  Jiali Leng; Qingxu Song; Yuguang Zhao; Zhenyu Wang
Journal:  Int J Oncol       Date:  2018-02-23       Impact factor: 5.650

6.  miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling.

Authors:  Matthew Knarr; Rita A Avelar; Sreeja C Sekhar; Lily J Kwiatkowski; Michele L Dziubinski; Jessica McAnulty; Stephanie Skala; Stefanie Avril; Ronny Drapkin; Analisa DiFeo
Journal:  Nat Commun       Date:  2020-06-26       Impact factor: 17.694

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.